News and research

News

PRECISION-ECS: three months in

Ethics approval, patient-derived melanoma models and the first cannabinoid tests mark the first three months of PRECISION-ECS.

News

From tumor sample to digital twin: feature on EndoVia’s approach in the University of Maribor magazine UMniverzum

News

TIKO-PRO publishes EndoVia’s EIC Pre-Accelerator success story

PRECISION-ECS is funded by the European Union under Horizon Europe grant agreement No 101310106.

News

Ethics approval for clinical study MEL-ECS-P01

The Slovenian National Medical Ethics Committee approved our non-interventional melanoma study with the Institute of Oncology Ljubljana, which establishes patient-derived melanoma models to study the endocannabinoid system.

News

University of Maribor announces EU funding for EndoVia’s personalized oncology platform

PRECISION-ECS is funded by the European Union under Horizon Europe grant agreement No 101310106.

News

PRECISION-ECS starts: EIC Pre-Accelerator project on predicting cannabinoid response in melanoma

PRECISION-ECS is funded by the European Union under Horizon Europe grant agreement No 101310106.

View the project on CORDIS ↗

News

EndoVia presents at EIC Day in Slovenia with the President of the EIC Board

SPIRIT Slovenia hosted Dr Michiel Scheffer, President of the European Innovation Council Board, together with the Ministry of Education, Science and Youth and Slovenian companies in the EIC Pre-Accelerator programme. Jan Rožanc presented EndoVia’s experience in the programme alongside Skylabs, ReCatalyst, FluidLab and MIDALIX, as part of a discussion on how Slovenian deep tech companies can make the most of EIC support.

News

Vesna Venture Capital invests in EndoVia

Vesna Venture Capital, a deep tech venture fund, has invested in EndoVia Therapeutics. The investment supports the development of our precision oncology platform, which uses digital twins of patient tumours to predict how individual tumours respond to cannabinoid-based therapies.

In the media

Finance

In the media

Večer · Interview

In the media

Maribor24 · Digital twin of tumors

In the media

Student.si

In the media

Startup.si · Company profile

Publication

Rožanc J, et al.

Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma.

Cell Death & Differentiation, 2019.

Publication

De Landtsheer S, Badkas A, Kulms D, Sauter T.

Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity.

Briefings in Bioinformatics, 2024.

Publication

Rukhlenko OS, et al. (incl. Rožanc J).

Dissecting RAF inhibitor resistance by structure-based modeling reveals ways to overcome oncogenic RAS signaling.

Cell Systems, 2018.

Publication

Ector C, et al. (incl. De Landtsheer S).

Circadian clock features define novel subtypes among breast cancer cells and shape drug sensitivity.

Molecular Systems Biology, 2025.

Publication

De Landtsheer S, et al.

FALCON: a toolbox for the fast contextualization of logical networks.

Bioinformatics, 2017.

Publication

De Landtsheer S, Lucarelli P, Sauter T.

Using regularization to infer cell line specificity in logical network models of signaling pathways.

Frontiers in Physiology, 2018.

Publication

Ravnik V, Jukič M, Furlan V, Maver U, Rožanc J, Bren U.

Uncovering the molecular targets of phytocannabinoids: mechanistic insights from inverse molecular docking fingerprint approaches.

Frontiers in Pharmacology, 2025.

Publication

Rozanc J, Klumpers LE, Huestis MA, Tagen M.

Tolerability of high-dose oral Δ9-THC: implications for human laboratory study design.

Cannabis and Cannabinoid Research, 2024.

Publication

Rožanc J, et al. (incl. Maver U).

Different Cannabis sativa extraction methods result in different biological activities against a colon cancer cell line and healthy colon cells.

Plants, 2021.

Publication

Skok K, et al. (incl. Maver U).

MFUM-BrTNBC-1, a newly established patient-derived triple-negative breast cancer cell line.

Cells, 2021.

Publication

Skok K, et al. (incl. Maver U).

Isolation and characterization of the first Slovenian human triple-negative breast cancer cell line.

The Breast Journal, 2020.